178 related articles for article (PubMed ID: 35344868)
1. Identification of secondary metabolites from Crescentia cujete as promising antibacterial therapeutics targeting type 2A topoisomerases through molecular dynamics simulation.
Aribisala JO; Abdulsalam RA; Dweba Y; Madonsela K; Sabiu S
Comput Biol Med; 2022 Jun; 145():105432. PubMed ID: 35344868
[TBL] [Abstract][Full Text] [Related]
2. Cheminformatics identification of modulators of key carbohydrate-metabolizing enzymes from
Balogun FO; Singh K; Rampadarath A; Akoonjee A; Naidoo K; Sabiu S
J Diabetes Metab Disord; 2023 Dec; 22(2):1299-1317. PubMed ID: 37969920
[TBL] [Abstract][Full Text] [Related]
3. DNA Topoisomerases as Targets for Antibacterial Agents.
Hiasa H
Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.
Chan PF; Srikannathasan V; Huang J; Cui H; Fosberry AP; Gu M; Hann MM; Hibbs M; Homes P; Ingraham K; Pizzollo J; Shen C; Shillings AJ; Spitzfaden CE; Tanner R; Theobald AJ; Stavenger RA; Bax BD; Gwynn MN
Nat Commun; 2015 Dec; 6():10048. PubMed ID: 26640131
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
9. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
Collins JA; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
[TBL] [Abstract][Full Text] [Related]
12. DNA gyrase and DNA topoisomerase of Bacillus subtilis: expression and characterization of recombinant enzymes encoded by the gyrA, gyrB and parC, parE genes.
Barnes MH; LaMarr WA; Foster KA
Protein Expr Purif; 2003 Jun; 29(2):259-64. PubMed ID: 12767818
[TBL] [Abstract][Full Text] [Related]
13. Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.
Leo E; Gould KA; Pan XS; Capranico G; Sanderson MR; Palumbo M; Fisher LM
J Biol Chem; 2005 Apr; 280(14):14252-63. PubMed ID: 15659402
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
[TBL] [Abstract][Full Text] [Related]
15. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.
Durcik M; Tomašič T; Zidar N; Zega A; Kikelj D; Mašič LP; Ilaš J
Expert Opin Ther Pat; 2019 Mar; 29(3):171-180. PubMed ID: 30686070
[TBL] [Abstract][Full Text] [Related]
16. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.
Franco-Ulloa S; La Sala G; Miscione GP; De Vivo M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401640
[TBL] [Abstract][Full Text] [Related]
17.
Roney M; Issahaku AR; Forid MS; Huq AKMM; Soliman MES; Mohd Aluwi MFF; Tajuddin SN
J Biomol Struct Dyn; 2023; 41(24):14904-14913. PubMed ID: 36995164
[TBL] [Abstract][Full Text] [Related]
18. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.
Drlica K; Mustaev A; Towle TR; Luan G; Kerns RJ; Berger JM
ACS Chem Biol; 2014 Dec; 9(12):2895-904. PubMed ID: 25310082
[TBL] [Abstract][Full Text] [Related]
19. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
20. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
